Coya Therapeutics announces the expansion of its research collaboration with the Houston Methodist Research Institute, HMRI, through a sponsored research agreement, SRA, covering multiple initiatives. The development and production of exosomes from patients’ regulatory T cells will be funded by the Johnson Center for Cellular Therapeutics with participation of the SRA from Coya to Dr. Stanley Appel, Director of the Johnson Center and Chair of Coya’s Scientific Advisory Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics files to sell 603,136 shares of common stock for holders
- Coya Therapeutics initiated with a Buy at Rodman & Renshaw
- Coya publishes ALS study in peer-reviewed Frontiers in Neurology
- Coya completes of Phase 2 study of LD IL-2 to treat moderate AD
- Coya Therapeutics announces $5M strategic investment from ADDF